ERBB2 and lung carcinoma: Currently, MCLA-128 is tested in clinical trials in patients with HER2-amplified and HER2-low/estrogen receptor-positive breast cancer, and in phase 1/2 trials in patients with NRG1-positive pancreatic and lung cancer (44).